Srinivas Akkaraju bought $8.1M of Mineralys Therapeutics (MLYS)
Executed Mar 13 2025, disclosed Mar 17 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 17 2025), the stock returned -2.5% (delay-adjusted); from the execution session (Mar 13 2025), -6.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Srinivas Akkaraju (Director) filed 12 Form 4 reports in the trailing twelve months (12 purchases, 1 sale, 2 filed past the two-business-day deadline; 1 filing reported both), most often in Alumis Inc. (ALMS). Across 11 priced purchase filings, the average 21-session return was +35.0% from execution and +27.3% from disclosure (delay-adjusted; derived). The largest single filing was $11.9M of SRRK (287,970 sh across 4 lots, as filed), executed Oct 23.
Healthcare · Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→588,235 sh × $25.50
Exec Sep 4 2025
Filed Sep 8 2025 · 8:07 PM ET